Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daletrectinib in Advanced Solid Tumors and Thymic Carcinoma
CTR20180996Phase 2Completed
- Sponsor
- Shanghai Institute of Materia Medica
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lucitanib in Nonhematologic neoplasms, thymic carcinoma (TC), sponsored by Shanghai Institute of Materia Medica. Started Jun 2018; status: completed.
02
Drugs
lucitanib
03
Conditions
Nonhematologic neoplasmsthymic carcinoma (TC)
Beyond the preview
Go deeper on CTR20180996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180996.